Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the... see more

NDAQ:ACST - Post Discussion

Acasti Pharma Inc > lots of misinformation going on here
View:
Post by LifeGoesOn1973 on Jan 03, 2020 7:50am

lots of misinformation going on here

1) regarding the Vascepa numbers, it is 33% improvement over placebo and not 24% as Francine said. 2) we already reduced TG by 15% in the severe strata in the 2 g in the Trifecta trial (confirmed by Pierre Lemieux in his latest Interview), Vascepa reduction was 7% so we are already double the values of Vascepa, does this trend continue with the 4 g ? I doubt it will be double but I am very optimistic. 3) regarding the recent drama in the SP, I acknowledge that management should have been less careless with the delay announcement by issuing the PR earlier but this is inconsequential because what matters the most is the quality of the results 4) Regarding talk about leak of the delays, ok it happens all the time leaks get out to privy investors this is not new so get over it, next time don't put stop losses in an extremely volatile sector. 5) The fact that company is willing to wait for secondary results before issuing the TG results is bullish since it is meaningless to issue secondary when primary fail. 6) regarding prediction of stock price, no one knows so stop speculating, analysts gives it up to 10 USD but again it depends on results, if we can equal or beat Vascepa with TG and prove better secondary then the sky is the limit, and if the HBA1c results prove reduction then expect additional increase of SP. 7) Right now all we can do is wait, lots of traders are playing this stock and the raid on Dec 23 is the biggest example, just ignore the noise and everyone's opinion (seeking alpha or VAS Research,, or others), don't put stop losses, go back to the fundamentals of the company, unless they change then just ignore the noise and wait for results
Comment by Stormdog01 on Jan 03, 2020 9:36am
@Lifegoeson1973 Excellent post! I tend to agree with most of your points. As for the Vascepa % TG reduction numbers, I believe the 24% is after the FDA requested calculation adjustment while the 33% is pre-adjustment, just like ACST got 36% and 38% with 1g and 2g pre FDA adjustment. Pierre Lemieux confirmed it is the pre-adjustment numbers that will be used to benchmark against the 20% primary ...more  
Comment by LifeGoesOn1973 on Jan 03, 2020 10:03am
thx Stormdog for the Vascepa correction , I was not aware of it and it never showed up in Vascepa NDA that they filed. but it goes back to the same, if the 20% required from Cape is the pre-adjustment number , then it should be compared to the pre-adjusted value of Vascepa , which is 33%. agree with you it is a slam dunk especially that we reached double the (pre-adjusted) value of vascepa in the ...more  
Comment by Francine01 on Jan 03, 2020 10:17am
Agree with everthing! Amen.  The 24% vs 33% was answered. Results could come any day soon starting monday, so i expect shorts to start covering.  Enjoy the ride. GLTA
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities